Susceptibility breakpoints are crucial for prudent use of antimicrobials. This study has developed the first susceptibility breakpoint (MIC < 0.25 g/ml) for enrofloxacin against swine Salmonella spp. based on wild-type cutoff (CO WT ) and pharmacokinetic-pharmacodynamic (PK-PD) cutoff (CO PD ) values, consequently providing a criterion for susceptibility testing and clinical usage of enrofloxacin.
and the traditional ciprofloxacin breakpoint against Salmonella (MIC Յ 1 g/ml) used in the 2002 to 2010 NARMS reports (6, 7). The higher CO WT in the present study may due to the different backgrounds of strains isolated from different hosts and different geographical areas. After single-dose intramuscular administration of enrofloxacin (2.5 mg/kg of body weight) to 12 piglets, concentrations of enrofloxacin in plasma were determined by high-performance liquid chromatography (HPLC) according to the method established in our lab (8) . The pharmacokinetic (PK) parameters were calculated using 3p97 software. Based on human clinical experience, an area under the concentration-time curve over 24 h in the steady state divided by the MIC (AUC/MIC ratio) value of Ն100 was assumed as pharmacokinetic-pharmacodynamic (PK-PD) target attainment for fluoroquinolones against Gram-negative organisms (9) . A 10,000-subject Monte Carlo simulation was constructed using Crystal Ball Professional version 7.2.2 software. The PK-PD susceptibility cutoff (CO PD ) was defined as the MIC at which the probability of target attainment (PTA) was Ն90% (4).
Our results were in agreement with previous studies which indicated that ciprofloxacin levels (an active metabolite of enrofloxacin) were too low in the plasma of pigs and enrofloxacin could be served as the marker for PK calculation (10, 11) . Based on the concentration-time curve of plasma enrofloxacin, a series of pharmacokinetic parameters for the 12 piglets were derived from a one-compartment model (see Table 1 ). After intramuscular administration of enrofloxacin, the peak drug concentration (C max ) and AUC were 0.74 Ϯ 0.38 g/ml and 15.87 Ϯ 3.39 g · h/ml, respectively. The probability of achieving various AUC/MIC ratios at each MIC value after a 10,000-pig Monte Carlo simulation is presented in Table 2 . At a MIC value of Յ0.25 g/ml, the probabilities of achieving AUC/MIC values of Ն100 were higher than 90%. Therefore, the CO PD of enrofloxacin against swine Salmonella was defined as a MIC value of Յ0.25 g/ml.
The CO PD in our study (MIC Յ 0.25 g/ml) was lower than the PK-PD breakpoint for ciprofloxacin recommended by EUCAST (MIC Յ 0.5 g/ml) and the susceptibility breakpoint for enrofloxacin against dog Enterobacteriaceae (MIC Յ 0.5 g/ml) recommended by CLSI M31-A3 (6, 12) . The lower PK-PD breakpoint in our study may be due to the lower dose of drug administration to pigs, because previous studies concluded that the dose of drug administration may affect the PK-PD breakpoint (11, 13, 14) . The PK-PD cutoff developed in our study should be more conservative, because it was generated based on the lowest approved dosage regimen for enrofloxacin (15) . Based on PK-PD models with the Monte Carlo simulation, a recent study established a ciprofloxacin breakpoint for Gram-negative aerobic bacteria (MIC Յ 0.125 g/ml) which was also much lower than the CLSI breakpoint and EUCAST breakpoint (16) . Both of the previous studies and our study suggested that CLSI may need to revise the breakpoint for some Gram-negative bacteria (16, 17) . Coincidently, a new susceptibility breakpoint for ciprofloxacin against Salmonella (MIC Ͻ 0.125 g/ml) was used in a 2011 NARMS report (7) . The discrepancy of susceptibility breakpoint may be due to drug specificity and geographical differences.
Conclusively, our study is unique in the sense that it has established a novel enrofloxacin susceptibility breakpoint against swine Salmonella spp. based on CO WT (MIC Յ 2 g/ml) and CO PD (MIC Յ 0.25 g/ml). Since the PK-PD cutoff provided greater value for setting the breakpoint than the wild-type cutoff did (15), the CO PD breakpoint (MIC Յ 0.25 g/ml) was finally selected as the optimum enrofloxacin susceptibility breakpoint for swine Salmonella. Although further clinical studies are necessary for confirming our findings, our work, to some extent, could provide a criterion for enrofloxacin susceptibility testing and improve prudent use of enrofloxacin for public health. 
